1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
Leelananda, S.P.; Lindert, S. Computational methods in drug discovery. Beilstein J. Org. Chem. 2016, 12,
2694–2718. [CrossRef] [PubMed]
Hayes, J.M. Chapter 2—Computer-aided discovery of glycogen phosphorylase inhibitors exploiting natural
products a2 —brahmachari, goutam. In Discovery and Development of Antidiabetic Agents from Natural Products;
Elsevier: Amsterdam, The Netherlands, 2017; pp. 29–62.
Langer, T. Pharmacophores in drug research. Mol. Inform. 2010, 29, 470–475. [CrossRef] [PubMed]
Voet, A.; Callewaert, L.; Ulens, T.; Vanderkelen, L.; Vanherreweghe, J.M.; Michiels, C.W.; De Maeyer, M.
Structure based discovery of small molecule suppressors targeting bacterial lysozyme inhibitors. Biochem.
Biophys. Res. Commun. 2011, 405, 527–532. [CrossRef] [PubMed]
Osman, G.; Omoshile, C.; Yasuhisa, K. Pharmacophore modeling and three dimensional database searching
for drug design using catalyst: Recent advances. Curr. Med. Chem. 2004, 11, 2991–3005.
Wolber, G.; Langer, T. Ligandscout: 3-d pharmacophores derived from protein-bound ligands and their use
as virtual screening filters. J. Chem. Inf. Modeling 2005, 45, 160–169. [CrossRef]
Yang, S.-Y. Pharmacophore modeling and applications in drug discovery: Challenges and recent advances.
Drug Discov. Today 2010, 15, 444–450. [CrossRef]
Rodolpho, C.B.; Carolina, H.A. Assessing the performance of 3d pharmacophore models in virtual screening:
How good are they? Curr. Top. Med. Chem. 2013, 13, 1127–1138.
Shin, W.-J.; Seong, B.L. Recent advances in pharmacophore modeling and its application to anti-influenza
drug discovery. Expert Opin. Drug Discov. 2013, 8, 411–426. [CrossRef]
Sanders, M.P.A.; McGuire, R.; Roumen, L.; de Esch, I.J.P.; de Vlieg, J.; Klomp, J.P.G.; de Graaf, C. From the
protein’s perspective: The benefits and challenges of protein structure-based pharmacophore modeling.
MedChemComm 2012, 3, 28–38. [CrossRef]
Langer, T.; Wolber, G. Pharmacophore definition and 3d searches. Drug Discov. Today Technol. 2004, 1,
203–207. [CrossRef]
Sci. Pharm. 2020, 88, 2
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
16 of 19
Horvath, D. Pharmacophore-based virtual screening. In Chemoinformatics and Computational Chemical Biology;
Bajorath, J., Ed.; Humana Press: Totowa, NJ, USA, 2011; pp. 261–298.
Lee, M.; Kim, D. Large-scale reverse docking profiles and their applications. BMC Bioinform. 2012, 13, S6.
[CrossRef] [PubMed]
Kumar, A.; Zhang, K.Y.J. Hierarchical virtual screening approaches in small molecule drug discovery. Methods
2015, 71, 26–37. [CrossRef] [PubMed]
Rognan, D. Docking methods for virtual screening: Principles and recent advances. In Virtual Screening;
Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2011; pp. 153–176.
Bajorath, J. Integration of virtual and high-throughput screening. Nat. Rev. Drug Discov. 2002, 1, 882.
[CrossRef] [PubMed]
Taft, C.A.; da Silva, V.B.; da Silva, C.H.T.d.P. Current topics in computer-aided drug design. J. Pharm. Sci.
2008, 97, 1089–1098. [CrossRef]
Song, C.M.; Lim, S.J.; Tong, J.C. Recent advances in computer-aided drug design. Brief. Bioinform. 2009, 10,
579–591. [CrossRef]
Hughes, J.P.; Rees, S.; Kalindjian, S.B.; Philpott, K.L. Principles of early drug discovery. Br. J. Pharmacol. 2011,
162, 1239–1249. [CrossRef]
Settivari, R.S.; Ball, N.; Murphy, L.; Rasoulpour, R.; Boverhof, D.R.; Carney, E.W. Predicting the future:
Opportunities and challenges for the chemical industry to apply 21st-century toxicity testing. J. Am. Assoc.
Lab. Anim. Sci. 2015, 54, 214–223.
Daniela, S.; Christian, L.; Theodora, M.S.; Thierry, L. Development and validation of an in silico p450 profiler
based on pharmacophore models. Curr. Drug Discov. Technol. 2006, 3, 1–48.
Rakers, C.; Schumacher, F.; Meinl, W.; Glatt, H.; Kleuser, B.; Wolber, G. In silico prediction of human
sulfotransferase 1e1 activity guided by pharmacophores from molecular dynamics simulations. J. Biol. Chem.
2016, 291, 58–71. [CrossRef]
Murgueitio, M.S.; Bermudez, M.; Mortier, J.; Wolber, G. In silico virtual screening approaches for anti-viral
drug discovery. Drug Discov. Today Technol. 2012, 9, e219–e225. [CrossRef]
Sakkiah, S.; Thangapandian, S.; John, S.; Lee, K.W. Pharmacophore based virtual screening, molecular
docking studies to design potent heat shock protein 90 inhibitors. Eur. J. Med. Chem. 2011, 46, 2937–2947.
[CrossRef] [PubMed]
Sanders, M.P.A.; Barbosa, A.J.M.; Zarzycka, B.; Nicolaes, G.A.F.; Klomp, J.P.G.; de Vlieg, J.; Del Rio, A.
Comparative analysis of pharmacophore screening tools. J. Chem. Inf. Modeling 2012, 52, 1607–1620.
[CrossRef] [PubMed]
Kitchen, D.B.; Decornez, H.; Furr, J.R.; Bajorath, J. Docking and scoring in virtual screening for drug discovery:
Methods and applications. Nat. Rev. Drug Discov. 2004, 3, 935. [CrossRef] [PubMed]
Ferreira, G.L.; dos Santos, N.R.; Oliva, G.; Andricopulo, D.A. Molecular docking and structure-based drug
design strategies. Molecules 2015, 20, 13384–13421. [CrossRef]
Naïm, M.; Bhat, S.; Rankin, K.N.; Dennis, S.; Chowdhury, S.F.; Siddiqi, I.; Drabik, P.; Sulea, T.; Bayly, C.I.;
Jakalian, A.; et al. Solvated interaction energy (sie) for scoring protein−ligand binding affinities. 1. Exploring
the parameter space. J. Chem. Inf. Modeling 2007, 47, 122–133.
Sulea, T.; Purisima, E.O. The solvated interaction energy method for scoring binding affinities. In Computational
Drug Discovery and Design; Baron, R., Ed.; Springer New York: New York, NY, USA, 2012; pp. 295–303.
Ota, S.; Tomioka, S.; Sogawa, H.; Satou, R.; Fujimori, M.; Karpov, P.; Shulga, S.; Blume, Y.; Kurita, N. Binding
properties between curcumin and malarial tubulin: Molecular-docking and ab initio fragment molecular
orbital calculations. Chem-Bio Inform. J. 2018, 18, 44–57. [CrossRef]
Kurauchi, R.; Watanabe, C.; Fukuzawa, K.; Tanaka, S. Novel type of virtual ligand screening on the basis of
quantum-chemical calculations for protein–ligand complexes and extended clustering techniques. Comput.
Theor. Chem. 2015, 1061, 12–22. [CrossRef]
Kitaura, K.; Sugiki, S.-I.; Nakano, T.; Komeiji, Y.; Uebayasi, M. Fragment molecular orbital method: Analytical
energy gradients. Chem. Phys. Lett. 2001, 336, 163–170. [CrossRef]
Sumanasinghe, N.; Mikler, A.R.; Muthukudage, J.; Tiwari, C.; Quiroz, R. Data driven prediction of dengue
incidence in thailand. In Recent Advances in Information and Communication Technology 2017: Proceedings of the
13th International Conference on Computing and Information Technology (ic2it); Meesad, P., Sodsee, S., Unger, H.,
Eds.; Springer International Publishing: Cham, Switzerland, 2018; pp. 95–107.
Sci. Pharm. 2020, 88, 2
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
17 of 19
Bhatt, S.; Gething, P.W.; Brady, O.J.; Messina, J.P.; Farlow, A.W.; Moyes, C.L.; Drake, J.M.; Brownstein, J.S.;
Hoen, A.G.; Sankoh, O.; et al. The global distribution and burden of dengue. Nature 2013, 496, 504–507.
[CrossRef]
Flipse, J.; Diosa-Toro, M.A.; Hoornweg, T.E.; van de Pol, D.P.I.; Urcuqui-Inchima, S.; Smit, J.M.
Antibody-dependent enhancement of dengue virus infection in primary human macrophages; balancing
higher fusion against antiviral responses. Sci. Rep. 2016, 6, 29201. [CrossRef]
Guzman, M.G.; Alvarez, M.; Halstead, S.B. Secondary infection as a risk factor for dengue hemorrhagic
fever/dengue shock syndrome: An historical perspective and role of antibody-dependent enhancement of
infection. Arch. Virol. 2013, 158, 1445–1459. [CrossRef] [PubMed]
Halstead, S.B.; O’Rourke, E.J. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by
non-neutralizing antibody. J. Exp. Med. 1977, 146, 201–217. [CrossRef] [PubMed]
The Lancet Infectious Diseases. The dengue vaccine dilemma. Lancet Infect. Dis. 2018, 18, 123. [CrossRef]
Aguirre, S.; Luthra, P.; Sanchez-Aparicio, M.T.; Maestre, A.M.; Patel, J.; Lamothe, F.; Fredericks, A.C.;
Tripathi, S.; Zhu, T.; Pintado-Silva, J.; et al. Dengue virus ns2b protein targets cgas for degradation and
prevents mitochondrial DNA sensing during infection. Nat. Microbiol. 2017, 2, 17037. [CrossRef] [PubMed]
Lim, S.P.; Noble, C.G.; Seh, C.C.; Soh, T.S.; El Sahili, A.; Chan, G.K.Y.; Lescar, J.; Arora, R.; Benson, T.; Nilar, S.;
et al. Potent allosteric dengue virus ns5 polymerase inhibitors: Mechanism of action and resistance profiling.
PLoS Pathog. 2016, 12, e1005737. [CrossRef] [PubMed]
Lindenbach, B.D.; Rice, C.M. Molecular biology of flaviviruses. In Advances in Virus Research; Academic
Press: Cambridge, MA, USA, 2003; Volume 59, pp. 23–61.
Ismail, N.A.; Jusoh, S.A. Molecular docking and molecular dynamics simulation studies to predict flavonoid
binding on the surface of denv2 e protein. Interdiscip. Sci. Comput. Life Sci. 2017, 9, 499–511. [CrossRef]
[PubMed]
Kuhn, R.J.; Zhang, W.; Rossmann, M.G.; Pletnev, S.V.; Corver, J.; Lenches, E.; Jones, C.T.; Mukhopadhyay, S.;
Chipman, P.R.; Strauss, E.G.; et al. Structure of dengue virus: Implications for flavivirus organization,
maturation, and fusion. Cell 2002, 108, 717–725. [CrossRef]
Cruz-Oliveira, C.; Freire, J.M.; Conceição, T.M.; Higa, L.M.; Castanho, M.A.R.B.; Da Poian, A.T. Receptors
and routes of dengue virus entry into the host cells. Fems Microbiol. Rev. 2015, 39, 155–170. [CrossRef]
Fuzo, C.A.; Degrève, L. The ph dependence of flavivirus envelope protein structure: Insights from molecular
dynamics simulations. J. Biomol. Struct. Dyn. 2014, 32, 1563–1574. [CrossRef]
Heinz, F.X.; Allison, S.L. Structures and mechanisms in flavivirus fusion. Adv. Virus Res. 2000, 55, 231–269.
Modis, Y.; Ogata, S.; Clements, D.; Harrison, S.C. A ligand-binding pocket in the dengue virus envelope
glycoprotein. Proc. Natl. Acad. Sci. USA 2003, 100, 6986–6991. [CrossRef] [PubMed]
Zhou, Z.; Khaliq, M.; Suk, J.-E.; Patkar, C.; Li, L.; Kuhn, R.J.; Post, C.B. Antiviral compounds discovered by
virtual screening of small–molecule libraries against dengue virus e protein. Acs Chem. Biol. 2008, 3, 765–775.
[CrossRef] [PubMed]
Wang, Q.-Y.; Patel, S.J.; Vangrevelinghe, E.; Xu, H.Y.; Rao, R.; Jaber, D.; Schul, W.; Gu, F.; Heudi, O.; Ma, N.L.;
et al. A small-molecule dengue virus entry inhibitor. Antimicrob. Agents Chemother. 2009, 53, 1823–1831.
[CrossRef] [PubMed]
Yennamalli, R.; Subbarao, N.; Kampmann, T.; McGeary, R.P.; Young, P.R.; Kobe, B. Identification of novel
target sites and an inhibitor of the dengue virus e protein. J. Comput. -Aided Mol. Des. 2009, 23, 333.
[CrossRef] [PubMed]
Schmidt, A.G.; Yang, P.L.; Harrison, S.C. Peptide inhibitors of dengue-virus entry target a late-stage fusion
intermediate. PLoS Pathog. 2010, 6, e1000851. [CrossRef] [PubMed]
Jadav, S.S.; Kaptein, S.; Timiri, A.; De Burghgraeve, T.; Badavath, V.N.; Ganesan, R.; Sinha, B.N.; Neyts, J.;
Leyssen, P.; Jayaprakash, V. Design, synthesis, optimization and antiviral activity of a class of hybrid dengue
virus e protein inhibitors. Bioorganic Med. Chem. Lett. 2015, 25, 1747–1752. [CrossRef]
Tambunan, U.S.F.; Zahroh, H.; Parikesit, A.A.; Idrus, S.; Kerami, D. Screening analogs of β-og pocket binder
as fusion inhibitor of dengue virus 2. Drug Target Insights 2015, 9, 33–49. [CrossRef]
Srivarangkul, P.; Yuttithamnon, W.; Suroengrit, A.; Pankaew, S.; Hengphasatporn, K.; Rungrotmongkol, T.;
Phuwapriasirisan, P.; Ruxrungtham, K.; Boonyasuppayakorn, S. A novel flavanone derivative inhibits
dengue virus fusion and infectivity. Antivir. Res. 2018, 151, 27–38. [CrossRef]
Sci. Pharm. 2020, 88, 2
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
18 of 19
De Wispelaere, M.; Lian, W.; Potisopon, S.; Li, P.-C.; Jang, J.; Ficarro, S.B.; Clark, M.J.; Zhu, X.; Kaplan, J.B.;
Pitts, J.D.; et al. Inhibition of flaviviruses by targeting a conserved pocket on the viral envelope protein. Cell
Chem. Biol. 2018, 25, 1006–1016. [CrossRef]
Kanyaboon, P.; Saelee, T.; Suroengrit, A.; Hengphasatporn, K.; Rungrotmongkol, T.; Chavasiri, W.;
Boonyasuppayakorn, S. Cardol triene inhibits dengue infectivity by targeting kl loops and preventing
envelope fusion. Sci. Rep. 2018, 8, 16643. [CrossRef]
Carneiro, B.M.; Batista, M.N.; Braga, A.C.S.; Nogueira, M.L.; Rahal, P. The green tea molecule egcg inhibits
zika virus entry. Virology 2016, 496, 215–218. [CrossRef]
Hengphasatporn, K.; Kungwan, N.; Rungrotmongkol, T. Binding pattern and susceptibility of epigallocatechin
gallate against envelope protein homodimer of zika virus: A molecular dynamics study. J. Mol. Liq. 2019,
274, 140–147. [CrossRef]
Barba-Spaeth, G.; Dejnirattisai, W.; Rouvinski, A.; Vaney, M.-C.; Medits, I.; Sharma, A.; Simon-Lorière, E.;
Sakuntabhai, A.; Cao-Lormeau, V.-M.; Haouz, A.; et al. Structural basis of potent zika–dengue virus antibody
cross-neutralization. Nature 2016, 536, 48–53. [CrossRef]
Slon Campos, J.L.; Marchese, S.; Rana, J.; Mossenta, M.; Poggianella, M.; Bestagno, M.; Burrone, O.R.
Temperature-dependent folding allows stable dimerization of secretory and virus-associated e proteins of
dengue and zika viruses in mammalian cells. Sci. Rep. 2017, 7, 966. [CrossRef]
Seyedi, S.S.; Shukri, M.; Hassandarvish, P.; Oo, A.; Shankar, E.M.; Abubakar, S.; Zandi, K. Computational
approach towards exploring potential anti-chikungunya activity of selected flavonoids. Sci. Rep. 2016, 6,
24027. [CrossRef]
Akimoto, N.; Ara, T.; Nakajima, D.; Suda, K.; Ikeda, C.; Takahashi, S.; Muneto, R.; Yamada, M.; Suzuki, H.;
Shibata, D.; et al. Flavonoidsearch: A system for comprehensive flavonoid annotation by mass spectrometry.
Sci. Rep. 2017, 7, 1243. [CrossRef]
Wieder, M.; Garon, A.; Perricone, U.; Boresch, S.; Seidel, T.; Almerico, A.M.; Langer, T. Common hits approach:
Combining pharmacophore modeling and molecular dynamics simulations. J. Chem. Inf. Modeling 2017, 57,
365–385. [CrossRef]
Chen, X.; Reynolds, C.H. Performance of similarity measures in 2d fragment-based similarity searching:
Comparison of structural descriptors and similarity coefficients. J. Chem. Inf. Comput. Sci. 2002, 42,
1407–1414. [CrossRef]
Irwin, J.J.; Shoichet, B.K. Zinc—A free database of commercially available compounds for virtual screening.
J. Chem. Inf. Modeling 2005, 45, 177–182. [CrossRef]
Manner, S.; Skogman, M.; Goeres, D.; Vuorela, P.; Fallarero, A. Systematic exploration of natural and synthetic
flavonoids for the inhibition of staphylococcus aureus biofilms. Int. J. Mol. Sci. 2013, 14, 19434–19451.
[CrossRef]
Berthold, M.R.; Cebron, N.; Dill, F.; Gabriel, T.R.; Kötter, T.; Meinl, T.; Wiswedel, B. Knime: The Konstanz
Information Miner. In Data Analysis, Machine Learning and Applications; Preisach, C., Burkhardt, H.,
Schmidt-Thieme, L., Decker, R., Eds.; Springer: Berlin/Heidelberg, Germany, 2008; pp. 319–326.
Fawcett, T. An introduction to roc analysis. Pattern Recognit. Lett. 2006, 27, 861–874. [CrossRef]
Mysinger, M.M.; Carchia, M.; Irwin, J.J.; Shoichet, B.K. Directory of useful decoys, enhanced (dud-e): Better
ligands and decoys for better benchmarking. J. Med. Chem. 2012, 55, 6582–6594. [CrossRef]
Wu, G.; Robertson, D.H.; Brooks, C.L.; Vieth, M. Detailed analysis of grid-based molecular docking: A case
study of cdocker—A charmm-based md docking algorithm. J. Comput. Chem. 2003, 24, 1549–1562. [CrossRef]
Hsu, K.-C.; Chen, Y.-F.; Lin, S.-R.; Yang, J.-M. Igemdock: A graphical environment of enhancing gemdock
using pharmacological interactions and post-screening analysis. BMC Bioinform. 2011, 12, S33. [CrossRef]
Csizmadia, F.; Tsantili-Kakoulidou, A.; Panderi, I.; Darvas, F. Prediction of distribution coefficient from
structure. 1. Estimation method. J. Pharm. Sci. 1997, 86, 865–871. [CrossRef]
Dixon, S.L.; Jurs, P.C. Estimation of pka for organic oxyacids using calculated atomic charges. J. Comput.
Chem. 1993, 14, 1460–1467. [CrossRef]
Wang, J.; Wolf, R.M.; Caldwell, J.W.; Kollman, P.A.; Case, D.A. Development and testing of a general amber
force field. J. Comput. Chem. 2004, 25, 1157–1174. [CrossRef]
Sangpheak, W.; Kicuntod, J.; Schuster, R.; Rungrotmongkol, T.; Wolschann, P.; Kungwan, N.; Viernstein, H.;
Mueller, M.; Pongsawasdi, P. Physical properties and biological activities of hesperetin and naringenin in
complex with methylated β-cyclodextrin. Beilstein J. Org. Chem. 2015, 11, 2763–2773. [CrossRef]
Sci. Pharm. 2020, 88, 2
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
19 of 19
Nutho, B.; Khuntawee, W.; Rungnim, C.; Pongsawasdi, P.; Wolschann, P.; Karpfen, A.; Kungwan, N.;
Rungrotmongkol, T. Binding mode and free energy prediction of fisetin/β-cyclodextrin inclusion complexes.
Beilstein J. Org. Chem. 2014, 10, 2789–2799. [CrossRef]
Kicuntod, J.; Khuntawee, W.; Wolschann, P.; Pongsawasdi, P.; Chavasiri, W.; Kungwan, N.; Rungrotmongkol, T.
Inclusion complexation of pinostrobin with various cyclodextrin derivatives. J. Mol. Graph. Model. 2016, 63,
91–98. [CrossRef]
Duan, Y.; Wu, C.; Chowdhury, S.; Lee, M.C.; Xiong, G.; Zhang, W.; Yang, R.; Cieplak, P.; Luo, R.; Lee, T.;
et al. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase
quantum mechanical calculations. J. Comput. Chem. 2003, 24, 1999–2012. [CrossRef]
Virtanen, S.I.; Niinivehmas, S.P.; Pentikäinen, O.T. Case-specific performance of mm-pbsa, mm-gbsa, and sie
in virtual screening. J. Mol. Graph. Model. 2015, 62, 303–318. [CrossRef]
Feyereisen, M.; Fitzgerald, G.; Komornicki, A. Use of approximate integrals in ab initio theory. An application
in mp2 energy calculations. Chem. Phys. Lett. 1993, 208, 359–363. [CrossRef]
Gordon, M.S.; Schmidt, M.W. Chapter 41—Advances in electronic structure theory: Gamess a decade later.
In Theory and Applications of Computational Chemistry; Dykstra, C.E., Frenking, G., Kim, K.S., Scuseria, G.E.,
Eds.; Elsevier: Amsterdam, The Netherlands, 2005; pp. 1167–1189.
Schmidt, M.W.; Baldridge, K.K.; Boatz, J.A.; Elbert, S.T.; Gordon, M.S.; Jensen, J.H.; Koseki, S.; Matsunaga, N.;
Nguyen, K.A.; Su, S.; et al. General atomic and molecular electronic structure system. J. Comput. Chem. 1993,
14, 1347–1363. [CrossRef]
Nakano, T.; Kaminuma, T.; Sato, T.; Akiyama, Y.; Uebayasi, M.; Kitaura, K. Fragment molecular orbital
method: Application to polypeptides. Chem. Phys. Lett. 2000, 318, 614–618. [CrossRef]
Ishimoto, T.; Tokiwa, H.; Teramae, H.; Nagashima, U. Theoretical study of intramolecular interaction energies
during dynamics simulations of oligopeptides by the fragment molecular orbital-hamiltonian algorithm
method. J. Chem. Phys. 2005, 122, 094905. [CrossRef]
Suroengrit, A.; Yuttithamnon, W.; Srivarangkul, P.; Pankaew, S.; Kingkaew, K.; Chavasiri, W.;
Boonyasuppayakorn, S. Halogenated chrysins inhibit dengue and zika virus infectivity. Sci. Rep. 2017, 7,
13696. [CrossRef]
Boonyasuppayakorn, S.; Suroengrit, A.; Srivarangkul, P.; Yuttithamnon, W.; Pankaew, S.; Saelee, T.;
Prompetchara, E.; Salakij, S.; Bhattarakosol, P. Simplified dengue virus microwell plaque assay using
an automated quantification program. J. Virol. Methods 2016, 237, 25–31. [CrossRef]
Flint, J.; Racaniello, V.R.; Rall, G.F.; Skalka, A.M.; Enquist, L.W. Principles of Virology, 4th ed.; ASM Press:
Washington, DC, USA, 2015; Volume I.
Brammer, L. Halogen bonding, chalcogen bonding, pnictogen bonding, tetrel bonding: Origins, current
status and discussion. Faraday Discuss. 2017, 203, 485–507. [CrossRef]
Cavallo, G.; Metrangolo, P.; Milani, R.; Pilati, T.; Priimagi, A.; Resnati, G.; Terraneo, G. The halogen bond.
Chem. Rev. 2016, 116, 2478–2601. [CrossRef]
Lisac, K.; Topi´c, F.; Arhangelskis, M.; Cepi´c, S.; Julien, P.A.; Nickels, C.W.; Morris, A.J.; Frišˇci´c, T.; Cinˇci´c, D.
Halogen-bonded cocrystallization with phosphorus, arsenic and antimony acceptors. Nat. Commun. 2019,
10, 61. [CrossRef]
Mendez, L.; Henriquez, G.; Sirimulla, S.; Narayan, M. Looking back, looking forward at halogen bonding in
drug discovery. Molecules 2017, 22, 1397. [CrossRef]
Maruyama, K.; Sheng, Y.; Watanabe, H.; Fukuzawa, K.; Tanaka, S. Application of singular value decomposition
to the inter-fragment interaction energy analysis for ligand screening. Comput. Theor. Chem. 2018, 1132,
23–34. [CrossRef]
Lu, Y.-X.; Zou, J.-W.; Wang, Y.-H.; Yu, Q.-S. Substituent effects on noncovalent halogen/π interactions:
Theoretical study. Int. J. Quantum Chem. 2007, 107, 1479–1486. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
...
論文の公開元へ
